Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» JPMHC 2023
JPMHC 2023
Will 2023 Usher in a New Era for Medtech M&A?
Medical Devices and Diagnostics Industry
Wed, 01/25/23 - 10:46 am
M&A
JPMHC 2023
Medtech
devices
At buzzy health care business conference, investors fear the bubble will burst
NPR
Fri, 01/20/23 - 10:22 am
JPMHC 2023
pandemic
COVID-19
3 biotech executives on the year ahead: deals, drug pricing and the down market
BioPharma Dive
Thu, 01/19/23 - 07:46 pm
JPMHC 2023
LifeMine
Ovid Therapeutics
Abio-X
Pharma CEOs
How 2 biotechs survived 2022’s rocky market—and why their CEOs see success on the horizon
Fierce Biotech
Wed, 01/18/23 - 11:12 pm
Agios Pharmaceuticals
Cerevel Therapeutics
JPMHC 2023
layoffs
A trio of biotechs consolidate as M&A fails to materialize at JPM
Fierce Biotech
Tue, 01/17/23 - 11:02 pm
JPMHC 2023
M&A
Leap Therapeutics
Flame Biosciences
JPM2023: Breakthroughs await, but so do roadblocks
Pharmaphorum
Fri, 01/13/23 - 10:09 am
JPMHC 2023
Inflation Reduction Act
cell therapy
gene therapy
clinical trials
CNS disorders
JPM23: Is GSK's 15-day accelerated approval withdrawal the new normal? Hear FDA Commissioner Robert Califf's response
Fierce Pharma
Thu, 01/12/23 - 09:20 pm
JPMHC 2023
GSK
Blenrep
clinical trial
FDA
Robert Califf
Did Storms Steal JPM's Thunder?
Medical Devices and Diagnostics Industry
Thu, 01/12/23 - 10:42 am
JPMHC 2023
San Francisco
JPM23: After rock climbing in biotech, Novartis' CMO is back to support hopeful hike to US summit
Fierce Biotech
Thu, 01/12/23 - 10:36 am
Novartis
JPMHC 2023
Dicerna Pharmaceuticals
Axcella Health
JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says
Fierce Pharma
Thu, 01/12/23 - 10:27 am
JPMHC 2023
Eli Lilly
pertibrutinib
donanemab
mirikizumab
lebrikizumab
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
BioPharma Dive
Wed, 01/11/23 - 11:08 pm
JPMHC 2023
Takeda
Bristol Myers Squibb
Prime Medicine
Sanofi
JPM23 squawk box: What’s changing – and what isn’t – at big healthcare companies
Medical Marketing and Media
Wed, 01/11/23 - 10:58 pm
JPMHC 2023
life sciences
biotech
executives
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
BioPharma Dive
Wed, 01/11/23 - 12:22 pm
JPMHC 2023
AbbVie
Richard Gonzalez
Pharma CEOs
Humira
Skyrizi
Rinvoq
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
BioPharma Dive
Wed, 01/11/23 - 12:16 pm
JPMHC 2023
FDA
Robert Califf
funding
venture capital
biotech
JPM23, Day 3: Takeda relishing in-person meetups
Fierce Biotech
Wed, 01/11/23 - 10:55 am
JPMHC 2023
Takeda
JPM23: Sanofi has reached the 'steady state' Paul Hudson envisioned years ago, CEO says
Fierce Pharma
Wed, 01/11/23 - 10:54 am
JPMHC 2023
Sanofi
Paul Hudson
Pharma CEOs
Dupixent
JPM Day 2: Highlights
BioSpace
Tue, 01/10/23 - 06:50 pm
JPMHC 2023
Relay Therapeutics
Sanofi
Scholar Rock
SAGE Therapeutics
Karuna Therapeutics
GSK
Merck Highlights Growth Strategy at J.P. Morgan
BioSpace
Tue, 01/10/23 - 06:48 pm
Merck
JPMHC 2023
Keytruda
vaccines
M&A
Amgen Boasts Lucrative Acquisitions, Drug Updates, Burgeoning Biosimilars at JPM
BioSpace
Tue, 01/10/23 - 06:43 pm
Amgen
JPMHC 2023
M&A
biosimilars
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
Fierce Biotech
Tue, 01/10/23 - 06:37 pm
JPMHC 2023
Karuna Therapeutics
drug launches
schizophrenia
KarXT
Pages
1
2
next ›
last »